Role of Adalimumab Biosimilar in the Treatment of Non-Anterior Uveitis Associated with Behcet's Syndrome

Introduction To evaluate the efficacy of SB5, an adalimumab biosimilar, in the management of Behcet's syndrome (BS)-related uveitis. Methods Data from eight BS patients (16 eyes) with active non-anterior uveitis and/or systemic uncontrolled disease or performing non-medical switch to SB5 were retrospectively collected and analyzed. Results Complete control of uveitis was observed in all 16 eyes without relapses during follow-up. The number of relapses 12 months prior to SB5 initiation and at last follow-up was 100 and 0 per 100 patients/year, respectively (p = 0.010). At baseline, four eyes had active retinal vasculitis, whereas at 3 months and at last follow-up, retinal vasculitis had resolved in all of them (p = 0.018). Median visual acuity did not vary significantly between baseline and last follow-up visit (p = 0.109). No ocular complications emerged during treatment. Conclusions SB5 is effective in the treatment of BS-related non-anterior uveitis. It reduces uveitis relapses and controls retinal vasculitis while allowing preservation of visual acuity.

Automated summary

The study demonstrates the significant efficacy of SB5 in treating Behcet's syndrome-related uveitis, showing its ability to control inflammation relapses, resolve retinal vasculitis, and preserve visual acuity.